吗氯贝胺与安慰剂治疗抑郁症的对比：比利时的一项多中心研究
Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.
作者信息
Botte L, Gilles C, Evrard J L, Mesters P, Wolfrum C, Berger M, Hellstern K, Ward J
机构信息
Centre Hospitalier de Tivoli, La Louvière, Belgium.
出版信息
Acta Psychiatr Scand Suppl. 1990;360:42. doi: 10.1111/j.1600-0447.1990.tb05323.x.
Moclobemide was compared with placebo for antidepressant activity, tolerance and safety in 2 parallel groups of 23 and 24 depressed patients. At the end of treatment (4 weeks or longer), 9 patients on moclobemide (41%) showed an improvement greater than or equal to 50% on the Hamilton Rating Scale for Depression, compared with only 4 (17%) of those on placebo. The overall assessment of efficacy was significantly better for moclobemide (good or very good results in 50% of patients) than for placebo (80% poor results). Moclobemide was well or very well tolerated by 85% of patients and placebo by 100%. Moclobemide was thus shown to be clearly more effective than placebo and only slightly less well tolerated.
在两个分别有23名和24名抑郁症患者的平行组中，对吗氯贝胺与安慰剂的抗抑郁活性、耐受性和安全性进行了比较。治疗结束时（4周或更长时间），服用吗氯贝胺的9名患者（41%）在汉密尔顿抑郁量表上的改善程度大于或等于50%，而服用安慰剂的患者中只有4名（17%）达到这一水平。吗氯贝胺的总体疗效评估（50%的患者效果良好或非常好）明显优于安慰剂（80%的患者效果差）。85%的患者对吗氯贝胺耐受性良好或非常好，对安慰剂耐受性良好的患者比例为100%。因此，吗氯贝胺显示出比安慰剂明显更有效，且耐受性只是略差。
Zotero 插件